Business Wire

Janssen Presents Results from Phase 3 ACIS Study in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Apalutamide ▼ and Abiraterone Acetate Combination

Share

FOR EMEA-BASED PHARMACEUTICAL TRADE AND MEDICAL MEDIA ONLY

NOT FOR DISTRIBUTION IN THE UK, BENELUX

The Janssen Pharmaceutical Companies of Johnson & Johnson today presented results from the randomised, placebo-controlled double-blind Phase 3 ACIS study, which met the primary endpoint of radiographic progression-free survival (rPFS) with a 31 percent reduction in the risk of radiographic progression or death in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) receiving androgen deprivation therapy (ADT). Patients in the trial received either a combination of apalutamide and abiraterone acetate plus prednisone (combination arm) or placebo and abiraterone acetate plus prednisone (control arm).1 Results will be featured in an oral presentation at the American Society of Clinical Oncology’s Genitourinary (ASCO GU) Cancers Symposium, taking place virtually February 11-13, 2021 (Abstract #9; Rapid Abstract Session: Prostate Cancer, February 11 06:45 AM-8:00 PM CET).

The primary efficacy analysis showed median rPFS was extended by six months in patients treated in the combination arm compared with patients in the control arm (22.6 vs 16.6 months; hazard ratio [HR] 0.69 [95% CI, 0.58-0.83]; p<0.0001). The HR for radiographic progression or death as assessed by blinded independent central review (BICR) was 0.864 [95% CI, 0.718–1.040]. According to an updated analysis performed at a median follow-up time of 54.8 months, a 30 percent reduction in the risk of radiographic progression or death was shown in the combination arm compared with the control arm (median time to rPFS 24 vs 16.6 months: HR 0.70 [95% CI, 0.60-0.83]). No statistically significant difference was demonstrated for secondary endpoints including overall survival (OS), time to initiation of cytotoxic chemotherapy, chronic opioid use, and pain progression between treatment arms.

The safety profile was consistent with prior studies of apalutamide, with no new safety signals observed. Grade 3/4 treatment emergent adverse events (TEAEs) were reported in 63.3 percent in the combination arm versus 56.2 percent in the control arm.1 Grade 3/4 TAEs that occurred more frequently in the combination versus control arm included fatigue (4.7 percent vs 3.9 percent), hypertension (20.6 versus 12.5 percent), fall (3.3 percent versus 0.6 percent), skin rash (4.5 percent vs. 0.4 percent), cardiac disorders (9 percent vs 5.7 percent), fractures and osteoporosis (4.1 percent vs 1.4 percent), and seizures (0.2 percent vs 0).1 Quality-of-life was comparable between treatment arms per Functional Assessment of Cancer Therapy–Prostate – (FACT-P Total).

##ENDS##

About the ACIS Study1

ACIS is a Phase 3 randomised, double-blind, placebo-controlled, multicentre clinical study evaluating the efficacy and safety of apalutamide and abiraterone acetate plus prednisone compared to placebo and abiraterone acetate plus prednisone in 982 patients with chemotherapy-naïve mCRPC disease who received ADT.1 Patients were randomised to receive either apalutamide and abiraterone acetate plus prednisone, or placebo and abiraterone acetate plus prednisone. The primary endpoint of the study was rPFS. Secondary endpoints of the study included OS, time to chronic opioid use, time to initiation of cytotoxic chemotherapy, and time to pain progression.1

About Metastatic Castration-Resistant Prostate Cancer

Metastatic castration-resistant prostate cancer (mCRPC) characterises cancer that no longer responds to ADT and has spread to other parts of the body. The most common metastatic sites are bones, followed by lymph nodes, lungs, and liver.2 Prostate cancer is the most common cancer in men in Europe, representing 25 percent of all male new cancer cases diagnosed.3 More than one million men around the world are diagnosed with prostate cancer each year.4

About apalutamide

Apalutamide is an orally administered, selective androgen receptor (AR) inhibitor approved in Europe and is indicated

  • in adult men for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease and
  • in adult men for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC), also known as metastatic castration-sensitive prostate cancer (mCSPC), in combination with androgen deprivation therapy (ADT).5

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

About abiraterone acetate

Abiraterone acetate, an orally administered androgen biosynthesis inhibitor, in combination with prednisone or prednisolone is approved in Europe for

  • the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT);
  • the treatment of metastatic castration resistant prostate cancer (mCRPC) in adult men who are asymptomatic or mildly symptomatic after failure of ADT in whom chemotherapy is not yet clinically indicated, and
  • the treatment of mCRPC in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen.6

Additionally, abiraterone acetate was approved for the treatment of high-risk metastatic hormone-sensitive prostate cancer (mHSPC) by the U.S. Food and Drug Administration (FDA) on February 8, 2018.7,8 Since its first approval in Europe in 2011, abiraterone acetate has been approved in combination with prednisone or prednisolone, in more than 105 countries and has been prescribed to more than 700,000 patients worldwide.9

About The Janssen Pharmaceutical Companies of Johnson & Johnson

At Janssen, we’re creating a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension.

Learn more at www.janssen.com/emea. Follow us at www.twitter.com/janssenEMEA for our latest news. Janssen Research & Development, LLC is part of the Janssen Pharmaceutical Companies of Johnson & Johnson.

Date of preparation: February 2021

Job code: CP-209565

###

Cautions Concerning Forward-Looking Statements

This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding potential benefits and further benefits of apalutamide. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialise, actual results could vary materially from the expectations and projections of Janssen Research & Development, LLC, any of the other Janssen Pharmaceutical Companies and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behaviour and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 30, 2019, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in the company’s most recently filed Quarterly Report on Form 10-Q, and the company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. None of the Janssen Pharmaceutical Companies nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.

References


1 Rathkopf. Dana E. Final Results From ACIS, a Randomized, Placebo (PBO)-Controlled Double-Blind Phase 3 Study of Apalutamide (APA) and Abiraterone Acetate Plus Prednisone (AAP) Versus AAP in Patients (Pts) With Chemo-Naive Metastatic Castration-Resistant Prostate Cancer (mCRPC). Abstract #9.

2 Cancer.org. Understanding advanced cancer, metastatic cancer, and bone metastasis. https://www.cancer.org/treatment/understanding-your-diagnosis/advanced-cancer/what-is.html. Last accessed February 2021.

3 HEAL. Men Prostate cancer. Available https://www.env-health.org/IMG/pdf/prostate_testical.pdf Last accessed February 2021.

4 World Health Organization. "Globocan 2012: Prostate Cancer: Incidence, Mortality and Prevalence Worldwide, 2012." http://gco.iarc.fr/today/data/pdf/fact-sheets/cancers/cancer-fact-sheets-19.pdf. Accessed February 2021.

5 European Medicines Agency. ERLEADA. Available at: https://www.ema.europa.eu/en/documents/product-information/erleada-epar-product-information_en.pdf. Last accessed February 2021.

6 European Medicines Agency. ZYTIGA. Available at: https://www.ema.europa.eu/en/documents/product-information/zytiga-epar-product-information_en.pdf, Last accessed February 2021.

7 ZYTIGA® U.S. Prescribing Information, October 2020.

8 Johnson & Johnson. Press Release. ZYTIGA® (abiraterone acetate) Plus Prednisone Approved for Treatment of Earlier Form of Metastatic Prostate Cancer. Available at: https://www.jnj.com/media-center/press-releases/zytiga-abiraterone-acetate-plus-prednisone-approved-for-treatment-of-earlier-form-of-metastatic-prostate-cancer. Last accessed January 2021

9 Data on file

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Inquiries:
Alexandra Nisipeanu
Mobile: +40 744 383 413
Email: adridean@its.jnj.com

Noah Reymond
Mobile: +31 621 385 718
Email: nreymond@its.jnj.com

Investor Relations:
Christopher DelOrefice
Office: +1 732 524 2955

Jennifer McIntyre
Office: +1 732 524 3922

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Nucleai and Merck KGaA Darmstadt, Germany Launch Translational Medicine Collaboration Utilizing Nucleai’s AI-Powered Biomarker Platform24.6.2021 17:17:00 CEST | Press release

Nucleai (www.nucleaimd.com), a precision medicine company using AI-powered image analysis technology to support novel pathology-based biomarker development, and Merck KGaA, Darmstadt, Germany, a leading science and technology company, announced that they have entered into a long-term collaboration to leverage Nucleai's image analysis and biomarker discovery platform for several Merck KGaA, Darmstadt, Germany clinical stage oncology assets. As part of the collaboration, Merck KGaA, Darmstadt, Germany will leverage Nucleai’s platform for exploratory research, with the potential to further develop identified pathology-based biomarkers as companion diagnostics. The collaboration will further utilize Nucleai’s technology to expand onto Merck KGaA, Darmstadt, Germany’s analysis capabilities, enabling faster turnaround time and scale for future studies. Nucleai's platform analyzes tissue images using computer vision and machine learning methods to model the tumor and the immune system's spati

Andersen Global Enters Collaboration Agreement With One of Lesotho’s Largest Law Firms24.6.2021 15:30:00 CEST | Press release

Andersen Global extends its African presence through a Collaboration Agreement with one of Lesotho’s largest law firms, Webber Newdigate Attorneys, enhancing the organization’s coverage in the southern region of the continent. Webber Newdigate Attorneys, established in 1978, is located in the capital city, Maseru. Recognized by Chambers Global and consistently awarded by PMR Africa, the full-service firm provides legal services to both local and international clients including individuals, companies, multinationals, government authorities, banks and parastatal organizations. The firm also covers a range of industries with capabilities in tax, real estate, employment law, corporate and commercial, litigation, banking and finance, mining and resources, immigration and family law. “For more than 40 years, our team has consistently delivered high-quality solutions to our clients, including those of an intricate nature,” said Partner Alex de Wet. “Andersen Global’s culture echoes our firm’s

New Outseer Fraud & Payments Report Confirms Massive Increase in Brand Abuse Cyber Attacks, Jumping 158% From Q1 202024.6.2021 15:00:00 CEST | Press release

Outseer has published its latest quarterly fraud and payments report, uncovering a significant spike in brand abuse attacks and a continued shift to more precise payment authentication methods. The Q2 installment of the report features insights from January through March of 2021 as captured through the Outseer Global Data Network, and collected while authenticating consumer transactions and investigating threats on behalf of Outseer customers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210624005352/en/ (Graphic: Business Wire) According to the report, Brand Abuse attacks impersonating companies through social media and published content now represents the majority of fraud attacks, growing from 27% in Q4 2020 to 68% in Q1 2021. This dramatic shift is attributed to the increased use of digital platforms including social media, web publishing, and cloud-based collaboration tools during the pandemic – all fertile hunting gr

Snow Software Recognizes Customer Excellence with Inaugural Technology Intelligence Awards24.6.2021 15:00:00 CEST | Press release

Snow Software, the global leader in technology intelligence, today announced the winners of its inaugural Technology Intelligence Awards. The awards recognize excellence in software, software-as-a-service (SaaS), SAP and cloud management. Winners were unveiled during the Snow User Summits on June 16 and 17. “We know that this past year has been especially difficult for many organizations around the world,” said Vishal Rao, President and CEO at Snow. “We introduced the Technology Intelligence Awards to recognize the outstanding work and incredible results our customers deliver every day, even in the face of such challenging circumstances. It is Snow’s way of thanking our customers for their continued partnership, celebrating the impact they are delivering for their organizations and ensuring we continue to help them thrive.” This year’s categories and winners are: Impact of the Year. Organizations that maximized value and contributed to strategic company initiatives by using one or more

IATA Strengthens Operational Scalability By Switching to Rimini Street for Integrated Support and Application Management Services for its SAP Applications24.6.2021 15:00:00 CEST | Press release

Rimini Street, Inc. (Nasdaq: RMNI), a global provider of enterprise software products and services, the leading third-party support provider for Oracle and SAP software products and a Salesforce partner, today announced that International Air Transport Association (IATA), the leading commercial aviation trade association headquartered in Montreal, Canada, has switched to Rimini Street Support and Application Management Services (AMS) for its SAP ECC 6.0 and Business Objects applications. With the commercial aviation sector heavily affected by the COVID-19 pandemic, IATA made strategic business decisions to navigate the crisis, including outsourcing key elements of its IT service delivery to reduce operating costs. As a result of switching to Rimini Street, the organization now benefits from a unified support solution that integrates application support and managed services, enabling IATA to meet business demand in a post-pandemic recovery. This press release features multimedia. View t

XPeng Inc. Launches Hong Kong Public Offering24.6.2021 14:59:00 CEST | Press release

XPeng Inc. (“XPeng” or the “Company”, NYSE: XPEV), a leading Chinese smart electric vehicle (“Smart EV”) company, today announced the launch of its Hong Kong public offering (the “Hong Kong Public Offering”), which forms part of the global offering (the “Global Offering”) of 85,000,000 new Class A ordinary shares of the Company (the “Offer Shares”) and listing of its Class A ordinary shares on the Main Board of The Stock Exchange of Hong Kong Limited (the “Hong Kong Stock Exchange”) under the stock code “9868” (the “Proposed Listing”). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210624005620/en/ XPeng P7 Wing edition (Photo: Business Wire) The Company’s American depositary shares (the “ADSs”), each representing two Class A ordinary shares of the Company, will continue to be listed and traded on the New York Stock Exchange (“NYSE”). The Proposed Listing is a dual-primary listing of the Class A ordinary shares of the Compan

Skyworks Aeronautics Announces the Order of 100 eGyro™ Electric Aircraft with Options for an Additional 100 by a Consortium of Mint Air and Mobius.energy24.6.2021 14:15:00 CEST | Press release

Today, Skyworks Aeronautics (“Skyworks”) announces the order of 100 eGyro™ electrically powered vertical take-off and landing (eVTOL) aircraft from a consortium of Mint Air (“Mint”) and Mobius.energy Corp (“Mobius”) with options for an additional 100 aircraft. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210624005323/en/ Notional depiction of the Skyworks eGyro™ (Photo: Business Wire) “A consortium led by Mint Air is committed to bringing safe, efficient, and cost-effective electric aircraft solutions to South Korea and we are absolutely thrilled they have selected our eGyro as their aircraft of choice to initiate operation of the leading eVTOL service in Korea. We look forward to performing our first public demonstrations of the eGyro in Korea and to launching the eGyro Urban Air Mobility (UAM) platform in the Korean market,” said John Michel, Co-Founder & Executive Director of Skyworks. “We are pleased to announce the Sk

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom